A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung Adenocarcinoma

Roche

Status: Completed

Conditions: Lung Adenocarcinoma

Treatments: Drug: Bevacizumab

Study type: Observational

Funder types: Industry

Identifiers

NCT02093000

ML29261

Details and patient eligibility

About

This prospective, open-label, single arm, non-interventional study will investigate the effectiveness of bevacizumab monotherapy in participants with lung adenocarcinoma who previously received 4 to 6 cycles of induction platinum doublet plus bevacizumab.

Enrollment: 201 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participant who previously received 4 to 6 cycles of induction platinum doublet plus bevacizumab
• Participant who received only 1 cycle of bevacizumab maintenance treatment
• Meet summary of product characteristics guidelines

Exclusion criteria

• Participant who received the first cycle of maintenance bevacizumab more than 4 weeks after the postinduction tumor assessment
• Pregnant or breast-feeding

Trial design

201 participants in 1 patient group

Bevacizumab

Description:

Participants who have received the induction phase of 4-6 cycles of bevacizumab plus platinum doublet chemotherapy will be treated with bevacizumab as maintenance treatment, according to approved label and local reimbursement.

Treatment:

Drug: Bevacizumab